<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/6878F160-3C35-4AC6-8D56-FBD6D6FB37B4"><gtr:id>6878F160-3C35-4AC6-8D56-FBD6D6FB37B4</gtr:id><gtr:name>Amgen Inc</gtr:name><gtr:address><gtr:line1>One Amgen Center Drive</gtr:line1><gtr:region>Outside UK</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/4D643118-D00D-43C5-A6C4-6035292F169C"><gtr:id>4D643118-D00D-43C5-A6C4-6035292F169C</gtr:id><gtr:name>Novartis</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/68D0E3C9-9246-4CFC-B5E9-48584CF82993"><gtr:id>68D0E3C9-9246-4CFC-B5E9-48584CF82993</gtr:id><gtr:name>University of Manchester</gtr:name><gtr:department>Life Sciences</gtr:department><gtr:address><gtr:line1>Oxford Road</gtr:line1><gtr:city>Manchester</gtr:city><gtr:postCode>M13 9PL</gtr:postCode><gtr:region>North West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/68D0E3C9-9246-4CFC-B5E9-48584CF82993"><gtr:id>68D0E3C9-9246-4CFC-B5E9-48584CF82993</gtr:id><gtr:name>University of Manchester</gtr:name><gtr:address><gtr:line1>Oxford Road</gtr:line1><gtr:city>Manchester</gtr:city><gtr:postCode>M13 9PL</gtr:postCode><gtr:region>North West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/6878F160-3C35-4AC6-8D56-FBD6D6FB37B4"><gtr:id>6878F160-3C35-4AC6-8D56-FBD6D6FB37B4</gtr:id><gtr:name>Amgen Inc</gtr:name><gtr:address><gtr:line1>One Amgen Center Drive</gtr:line1><gtr:region>Outside UK</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/4D643118-D00D-43C5-A6C4-6035292F169C"><gtr:id>4D643118-D00D-43C5-A6C4-6035292F169C</gtr:id><gtr:name>Novartis</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/DC247267-DA2E-47CD-838A-348F17241C68"><gtr:id>DC247267-DA2E-47CD-838A-348F17241C68</gtr:id><gtr:firstName>Nancy</gtr:firstName><gtr:otherNames>Jane</gtr:otherNames><gtr:surname>Rothwell</gtr:surname><gtr:roles><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G19%2F41"><gtr:id>7B8D8978-FAE6-4DED-91DC-913B16259216</gtr:id><gtr:title>Mechanisms of interleukin-1 action in neuronal injury</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Fellowship</gtr:grantCategory><gtr:grantReference>G19/41</gtr:grantReference><gtr:abstractText>Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.</gtr:abstractText><gtr:technicalSummary>Mechanisms of interleukin-1 action in neuronal injury</gtr:technicalSummary><gtr:fund><gtr:end>2010-06-30</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2008-12-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>465851</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Amgen Inc</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>Provision of Amgen IL-1RA for clinical studies</gtr:description><gtr:id>BC2687EB-1CF0-45F9-9520-35CE84222816</gtr:id><gtr:impact>Pharmacokinetic study identified optimal dosing regime of IL-1RA in SAH patients to take forward to test efficacy in further trials. Phase II randomised controlled double blind trial (IL-1RA vs placebo) now completed in SAH patients (analysis in progress).</gtr:impact><gtr:outcomeId>8751115D3FF-1</gtr:outcomeId><gtr:partnerContribution>Provision of IL-1RA for clinical studies</gtr:partnerContribution><gtr:piContribution>Carried out pharmacokinetic study to identify optimal dosing regime of IL-1RA in SAH patients.</gtr:piContribution><gtr:sector>Private</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Novartis</gtr:collaboratingOrganisation><gtr:country>Global</gtr:country><gtr:description>Testing of Novartis's anti-IL-1beta antibody in cerebral ischaemia and neuroinflammation</gtr:description><gtr:id>1A85C713-6508-42BA-9910-EC968671681F</gtr:id><gtr:impact>Cerebral ischaemia experiments ongoing.
Neuroinflammation experiments finished (in collaboration with cardiovascular colleagues at the University of Sheffield - 3-way agreement); paper in preparation and pending approval from Novartis prior to submission.</gtr:impact><gtr:outcomeId>2D379C81C87-1</gtr:outcomeId><gtr:partnerContribution>Provision of material for studies</gtr:partnerContribution><gtr:piContribution>We will test this antibody for neuroprotection in experimental models of cerebral ischaemia and neuroinflammation.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>International Women's Day, Manchester</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>252E6922-BAE8-4D44-8E96-CB7B68C81DAF</gtr:id><gtr:impact>Guest speaker at dinner for International Women's Day, Manchester, to ~150 members of the general public.

None known</gtr:impact><gtr:outcomeId>r24oDd2Vwjb</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Give approx. 10-12 public and schools lectures each year (too numerous to detail)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:id>EBFB7DFE-57F5-47CF-8CA4-386A8D5DDFC3</gtr:id><gtr:impact>Give approx. 10-12 public and schools lectures each year (too numerous to detail)

Not possible to detail specific impacts - aim to increase interest in science, particularly in underprivileged areas. Often receive requests from school students wishing to do work experience in the lab, following a talk at their school (all of whom we aim to accommodate wherever possible).</gtr:impact><gtr:outcomeId>8455F4C626C</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2009</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Biomedical Sciences PhD Student Society, King's College London</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>6A583B4B-A559-4A79-9856-D682DB79331A</gtr:id><gtr:impact>Gave talk on career in science to students, which sparked questions and discussion.

None known</gtr:impact><gtr:outcomeId>WhKXEVL559k</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Postgraduate students</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Cheltenham Science Festival</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>FD01FA92-D2D8-4530-B043-674B165D3EBA</gtr:id><gtr:impact>Gave a talk on &amp;quot;A stroke of bad luck&amp;quot; to ~200 members of the general public, which sparked questions and discussion.

None known</gtr:impact><gtr:outcomeId>ALvkUibC9Sg</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:url>http://www.cheltenhamfestivals.com/science/whats-on/2013/stroke/</gtr:url><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Frontiers of Science talk, Uni of Manchester</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:id>41692A26-B00D-4774-B81E-EE37B6CD7278</gtr:id><gtr:impact>Frontiers of Science talk delivered to ~150 undergraduate students from 1st year to 3rd year, followed by questions and discussion. 
Title: &amp;quot;Flaming brains - new discoveries about brain disease&amp;quot;


No specific impact known.</gtr:impact><gtr:outcomeId>C55QFTfaDfg</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Lecture at the University of Birmingham</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:id>3EAC399F-F840-400F-85E3-A069821C6E50</gtr:id><gtr:impact>Talk title: &amp;quot;A stroke of bad luck: mechanisms and treatments for brain disease&amp;quot;. For ~200 Uni staff and students. Followed by questions and discussion.

No specific impact known.</gtr:impact><gtr:outcomeId>r8vUB86TSKs</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Annual STARS lecture, Manchester</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:id>6E146B30-682B-46E4-9D61-C9F80A39BF94</gtr:id><gtr:impact>Annual STARS lecture to ~200 local sixth form and college students.
Title: 'A stroke of bad luck: Understanding brain disease' (targeted at A level Biology).

Not known.</gtr:impact><gtr:outcomeId>PFRnDs3rxGz</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Numerous scientific, public and policy talks - too many to detail</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:id>001A73F4-FE84-4F2C-B550-D5043B5E175B</gtr:id><gtr:impact>Numerous scientific, public and policy talks - too many to detail.

Significant press coverage</gtr:impact><gtr:outcomeId>1716FB71527</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2006,2007,2008</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Event for stroke patients and carers, Nov. 2010</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:id>DC50EF31-EC23-4B94-B955-047C38D0E42F</gtr:id><gtr:impact>10 stroke survivors/carers attended an event called &amp;quot;Stroke research - from test tube to treatment&amp;quot;, which comprised talks from 3 researchers, spanning preclinical to clinical studies, and interacted with post-docs and students over various displays and refreshments. The feedback from attendees was mostly very positive and all but one expressed an interest in attending future events. The constructive feedback has made us re-evaluate what we want to achieve from such events and will inform future events.

We are re-evaluating the aims of such events and are planning further, larger events, taking into account the feedback received from this meeting. Specifically, we will be involved in a large event for World Stroke Day 2011, with our clinical colleagues.</gtr:impact><gtr:outcomeId>ehMi5Arfh5S</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2010</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Francis Crick Institute Postdoc Conference</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>F42047FD-3F80-481C-AC4E-0126773D837C</gtr:id><gtr:impact>Talk on Career in Science to ~300 students and young researchers across London, which sparked questions and discussion.

None known</gtr:impact><gtr:outcomeId>Xp8hzjGDVMn</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Postgraduate students</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>World Stroke Day 2011</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:id>6D6D0836-263F-4FC6-BE00-7754DBA22654</gtr:id><gtr:impact>World Stroke Day event in Oct. 2011 organised by our clinical colleagues. The clinical investigator Dr Tyrrell presented the results of the clinical study funded by this grant. The audience comprised ~180 stroke patients and their carers, healthcare professionals and associated charities/organisations.

Not known.</gtr:impact><gtr:outcomeId>kf5b4x2Axs7</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Keynote lecture to Schools Science Conference 2011</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:id>EE827125-F01D-49A4-8FE7-722E1C71191E</gtr:id><gtr:impact>Talk followed by Q&amp;amp;A session. Title: &amp;quot;A stroke of bad luck - new discoveries in the treatment of brain disease&amp;quot;. Session: Science is the Future.
Venue : Royal College of Pathologists, London
Audience : 50 secondary year students from years 10-13 and their teachers

No specific impact known.</gtr:impact><gtr:outcomeId>Lk5nSPG9mMS</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Highgate Literary and Scientific Institution, London</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>8CB54A74-F38B-4AD9-A48E-F509FA03EE27</gtr:id><gtr:impact>Lecture to ~100 local citizens on my research, which sparked questions and discussion

None known</gtr:impact><gtr:outcomeId>sZzPA9L69wC</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>640000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC Models of Disease Grant</gtr:description><gtr:end>2012-08-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:fundingRef>G0801040</gtr:fundingRef><gtr:id>88CEEDFE-CE1C-4E6E-AF04-F6E67A9C2E88</gtr:id><gtr:outcomeId>188400202F00</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2008-12-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>600000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Developmental Clinical Studies</gtr:description><gtr:end>2014-04-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:fundingRef>G1001252</gtr:fundingRef><gtr:id>8DB94EF6-A83F-4BF5-A324-BAFFE6847C9D</gtr:id><gtr:outcomeId>Dt7ETj7QHm60</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-05-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>31C8C057-5ECA-4FBD-94FA-4477E191DBA1</gtr:id><gtr:title>[18F]DPA-714: direct comparison with [11C]PK11195 in a model of cerebral ischemia in rats.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0a38ec850e295c845988913ac982a36d"><gtr:id>0a38ec850e295c845988913ac982a36d</gtr:id><gtr:otherNames>Boutin H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>pm_14197_27_23418569</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D61F522B-AF49-4545-A5B9-D177702BBB45</gtr:id><gtr:title>Cerebrospinal fluid and plasma cytokines after subarachnoid haemorrhage: CSF interleukin-6 may be an early marker of infection.</gtr:title><gtr:parentPublicationTitle>Journal of neuroinflammation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f71d3aaa7a3c0bfe33cc8b301144c16b"><gtr:id>f71d3aaa7a3c0bfe33cc8b301144c16b</gtr:id><gtr:otherNames>Hopkins SJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1742-2094</gtr:issn><gtr:outcomeId>pm_14197_27_23176037</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>27F11802-2FAD-408B-A74E-395A4C8D524F</gtr:id><gtr:title>Interleukin-1 receptor antagonist reverses stroke-associated peripheral immune suppression.</gtr:title><gtr:parentPublicationTitle>Cytokine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/96b97ef1a88f6699dbff7bc9113ed7db"><gtr:id>96b97ef1a88f6699dbff7bc9113ed7db</gtr:id><gtr:otherNames>Smith CJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1043-4666</gtr:issn><gtr:outcomeId>pm_14197_27_22445501</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8D09561C-2397-43A4-8191-E5CC9C1FB979</gtr:id><gtr:title>Inflammation as a predictor for delayed cerebral ischemia after aneurysmal subarachnoid haemorrhage.</gtr:title><gtr:parentPublicationTitle>Journal of neurointerventional surgery</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d584eae4f1cfd13ea06d51d5cf6ba27d"><gtr:id>d584eae4f1cfd13ea06d51d5cf6ba27d</gtr:id><gtr:otherNames>McMahon CJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1759-8478</gtr:issn><gtr:outcomeId>pm_14197_27_22952245</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4191B4BD-2B38-49E6-9F00-949174A0767C</gtr:id><gtr:title>An immortalised astrocyte cell line maintains the in vivo phenotype of a primary porcine in vitro blood-brain barrier model.</gtr:title><gtr:parentPublicationTitle>Brain research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5e5b3208b5a60de428d4f4eba554d7a0"><gtr:id>5e5b3208b5a60de428d4f4eba554d7a0</gtr:id><gtr:otherNames>Cantrill CA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0006-8993</gtr:issn><gtr:outcomeId>pm_14197_27_22940232</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G19/41</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>D4FDB752-4E9C-491F-9C63-B7D7F6F95417</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Cardiovascular</gtr:text></gtr:healthCategory><gtr:healthCategory><gtr:id>C6D70A71-8796-47BC-AFE0-CC2286E66A06</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Inflammatory and Immune System</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>